Mark Sausen

9PUBLICATIONS
119CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 23, 2026
Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.

|Apr 19, 2026
plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.

|Jan 14, 2026
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation.

Jonathan Baden, Cheng-Ho Jimmy Lin, Andrew T Anfora

|Nov 10, 2025
CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness.

Haoyue Wang, Astrid Kramer, Marjolein J E Greuter

|Nov 03, 2025
Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.

Seka Lazare, Zhuosheng Gu, Noah Earland

|May 11, 2024
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages.

Brittany A McKelvey, Hillary S Andrews, Frederick L Baehner

Pageof 2

Frequent Collaborators

3 joint publications

Victor E Velculescu

3 joint publications

Valsamo Anagnostou

3 joint publications

Gerrit A Meijer

3 joint publications

Remond J A Fijneman